Eurofins-Cerep

Regulatory Filings • Jun 15, 2009

Cerep announces Kinase profiling agreement with Lilly

Paris, France, June 15, 2009 - press release 2009/06

Cerep SA, a leading provider of drug candidate screening and profiling technologies, today announced the signature of a kinase-based profiling agreement with Eli Lilly and Company.

Under the terms of the agreement, Cerep will provide Lilly with access to the company's expanded kinase assay platform for research into undisclosed drug targets. The kinase agreement builds on a prior agreement between the two companies for access to Cerep's GPCRs portfolio.

The agreement follows the recently-announced expansion of kinases portfolio made available by Cerep in collaboration with PerkinElmer, Inc., whose LANCE® UltraTM kinase assay technology forms the basis of the offering.

Cerep's total kinase platform now includes screening capabilities for 250 targets with a broad range of assays for cancer, cardiac diseases, central nervous system disorders, inflammation, diabetes, metabolic disorders, among other major disease states.

Thierry Jean, Chairman and CEO of Cerep, commented: "This agreement further illustrates that our long term strategy to broaden our leadership position in drug discovery services, together with key decisions taken over the past few years - such as the collaboration signed with Perkin Elmer - are continuously resulting in additional cost effective and high quality services for our customers and partners".

About Cerep SA

Focussing on in vitro pharmacology and ADME-Tox, Cerep [Nyse Euronext – CER] provides solutions allowing cost-effective drug discovery by identifying at early stages the most promising drug candidates and eliminating compounds likely to fail in development. Cerep's technologies benefit to more than 460 pharmaceutical and biotechnological companies worldwide including most of the top pharmaceutical firms.

Contacts

Thierry Jean, Chairman & CEO Sophie Macault, General Counsel & Corporate Secretary Tel. +33 (0)1 45 64 44 60 fincom@cerep.fr

Code ISIN FR0004042232 Euronext Paris Euronext - Local Securities

Cerep SA 155 boulevard Haussmann 75008 Paris France tel + 33(0)145 64 44 60 fax +33(0)145 64 44 64 e-mail: fincom@cerep.fr www.cerep.com

Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements" for purposes of the safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forwardlooking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company's proprietary rights and other factors described in the company's Annual Financial Report.